Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.
4 reports, 2 independent
Updated Sep 17
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Exelixis participated in a Morgan Stanley conference and is assessing international assets.1 source
Morgan Stanley increased its stake in Exelixis.1 source
Morgan Stanley provided positive ratings for Exelixis, which MarketBeat aggregated.1 source
Keep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Exelixis
American biotechnology company
Nothing else this week.
-
MarketBeat
American personal finance blog
Related events
- MarketBeat reported an average stock rating for Superior Group of Companies.
- MarketBeat reports consensus rating for Expedia Group, while Morgan Stanley and DBS Bank upgrade their ratings/target prices for the company.
- MarketBeat reported recent stock ratings for Innovative Solutions and Support, Inc. and TechPrecision Corporation.
- MarketBeat is providing analyst ratings and targets for Addentax Group and Expeditors International of Washington, Inc.
- Exelixis stock trades on the Nasdaq electronic stock exchange.